Streetbeat News

Stock Prices

ARBK

ATGL

BKYI

CLRO

CTM

DATS

DTSS

FOXO

MOB

MTC

SASI

TAOP

In Friday's pre-market session, several information technology stocks showed significant movement. FOXO Technologies (FOXO) led the gainers with a 23.6% increase, while DatChat (DATS) experienced the largest drop among the losers, falling 15.8%. Other notable gainers include Mobilicom (MOB), Alpha Technology Group (ATGL), Taoping (TAOP), Sigma Additive Solutions (SASI), and BIO-key Intl (BKYI). On the losing side, MMTEC (MTC), Datasea (DTSS), Argo Blockchain (ARBK), Castellum (CTM), and ClearOne (CLRO) also saw their share prices decline.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 1:05 pm

CLF

IBM

RSP

UBER

On CNBC's 'Halftime Report Final Trades,' analysts recommended IBM, RSP, CLF, and UBER. IBM acquired StreamSets and webMethods for €2.13 billion. RSP was picked by Bryn Talkington. CLF, previously interested in acquiring U.S. Steel, is refocusing on share buybacks. UBER reached a 52-week high and plans to enter Japan's taxi market with Tesla vehicles. IBM and RSP shares slightly gained, while CLF and UBER shares saw minor declines.

Portfolio Pulse from Avi Kapoor

December 29, 2023 | 1:01 pm

TSLA

Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management and a Tesla investor, expressed concerns about the potential negative impact of Elon Musk's 'extreme' behavior on Tesla's sales. Gerber believes that while some consumers will continue to buy Tesla for its value, others may be deterred by Musk's actions and opt for other EV brands. Despite this, Gerber remains bullish on Tesla in the long term. A recent study suggests that Musk's behavior has little to no impact on many consumers' decisions to buy Tesla vehicles, with some even more inclined to purchase due to Musk.

Portfolio Pulse from Anan Ashraf

December 29, 2023 | 1:01 pm

ACAD

Analysts have provided varying ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the last quarter, with a total of 13 ratings ranging from bullish to bearish. The average 12-month price target for ACAD is $34.08, with a high estimate of $42.00 and a low estimate of $25.00, marking a 13.15% increase from the previous average of $30.12. Several analysts have raised their price targets and ratings, indicating a positive outlook on the company's performance. ACADIA Pharmaceuticals is a biotech company focusing on CNS disorders and has shown a revenue growth rate of 61.96% as of September 30, 2023, but with a net margin of -30.79% and an ROA of -10.22%. The company's market capitalization is below the industry average, and it has a debt-to-equity ratio of 0.16.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 1:00 pm

COP

Eight analysts have recently updated their ratings on ConocoPhillips (NYSE:COP), with a mix of bullish and neutral stances. The average 12-month price target is $140.38, with a high of $152.00 and a low of $125.00, marking a 1.75% decrease in the average target. Analysts from firms like Raymond James, UBS, JP Morgan, RBC Capital, Susquehanna, Jefferies, and Morgan Stanley have adjusted their ratings and price targets. ConocoPhillips is a major oil and gas producer with strong financial indicators such as a high net margin and ROE, but it has experienced a significant revenue decline in the last quarter.

Portfolio Pulse from Benzinga Insights

December 29, 2023 | 1:00 pm

HQL

Saba Capital Management has disclosed a 5.31% ownership stake in abrdn Life Sciences, as indicated in a 13D filing. The filing suggests that Saba Capital may be taking an active interest in the company, which could lead to potential changes in business strategy, management, or operations.

Portfolio Pulse from Charles Gross

December 29, 2023 | 1:00 pm

NRBO

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares dropped in Friday's premarket session by 4.76% to $3.81 after a 21.2% gain the previous day. The decline follows the company's submission of an IND application to the FDA for a Phase 1 trial of DA-1726, a novel treatment for obesity. DA-1726 has shown promising preclinical results, outperforming existing treatments like semaglutide and tirzepatide in animal models. The Phase 1 trial will be randomized, placebo-controlled, double-blind, and will have two parts: a single ascending dose study and a multiple ascending dose study.

Portfolio Pulse from Nabaparna Bhattacharya

December 29, 2023 | 12:59 pm

NLY

Annaly Capital Management, Inc. (NLY) shares closed flat despite the S&P 500 nearing record levels. Analyst Bose George maintained an Outperform rating and raised the price target from $17 to $21.50. The company reported a Q3 GAAP loss of $1.21 per share. Shares rose 10% over the past month but fell 7% YTD. Annaly offers a high dividend yield of 13.08%, equating to a quarterly dividend of 65 cents per share. To earn $500 monthly in dividends, an investor would need 2,308 shares, valued at approximately $45,883. The article also explains how dividend yield fluctuates with stock price and dividend changes. NLY shares were down 3.1% to $19.88 on Thursday.

Portfolio Pulse from Avi Kapoor

December 29, 2023 | 12:50 pm

LYFT

QQQ

SPY

TSLA

UBER

Ahead of the final trading session of 2023, Nasdaq and S&P 500 futures are flat, with the broader market potentially setting a record close. The S&P 500 is close to an all-time high, and the market is expected to have low volume due to the New Year holiday. Thursday's trading closed mixed, with the S&P 500 nearing its record and Nasdaq slightly down. Analyst Louis Navellier predicts AI to be a major theme and expects energy, consumer staples, utilities, and healthcare to do well in 2024. SPDR S&P 500 ETF Trust (SPY) and Invesco QQQ ETF (QQQ) saw slight premarket gains. Tesla (TSLA) is up in premarket trading, while Lyft (LYFT) and Uber (UBER) are down. Economic data to watch includes the Chicago ISM manufacturing survey.

Portfolio Pulse from Shanthi Rexaline

December 29, 2023 | 12:45 pm

BSX

BTIG analyst Marie Thibault has reiterated a Buy rating on Boston Scientific (NYSE:BSX) and maintained a price target of $64.

Portfolio Pulse from Benzinga Newsdesk

December 29, 2023 | 12:43 pm